GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS) from its SEC filings: 2025 revenue $427.5 million (+40% vs the year before), net margin -5%, free cash flow $14.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Health Services |
| Revenue (2025) | $427.5 million |
| Revenue growth | +40% |
| Net income | -$21.0 million |
| Net margin | -4.9% |
| Free cash flow | $14.3 million |
| Diluted EPS | $-0.73 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +11% |
| Cash | $60.3 million |
| Long-term debt | $96.8 million |
| Share count, 1 year | +4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.